해시 게임 바카라rategic acquisition to propel Dong-A 해시 게임 바카라’s R&D capabilities and pipeline expansion
Dong-A ST, under the leadership of Min-Young Kim, announced the acquisition of specialized Antibody-Drug Conjugate (해시 게임 바카라) company, AbTis, on December 20th, marking a significant stride in bolstering its research and development (R&D) sector.
Dong-A ST has solidified its growth strategy with the acquisition of AbTis, encompassing management rights, third-generation 해시 게임 바카라 linker platform technology, and pipeline. The anticipated subsidiary status of AbTis under Dong-A ST by year-end heralds a new phase in the company's trajectory.
The company's roadmap post-acquisition involves the advancement of AbTis' 해시 게임 바카라 anticancer pipeline, leveraging existing technology while venturing into innovative platforms like Antibody Radionuclide Conjugate (ARC), Antibody PROTAC Conjugate (APC), and Immune-Stimulating Antibody Conjugate (ISAC).
Emphasizing synergy across Dong-A ST, ST Pharm, and STgen Bio, the company aims to fortify its 해시 게임 바카라 platform technology in the medium to long term, extending operations into 해시 게임 바카라 contract development and manufacturing organization (CDMO) businesses.
AbTis' hallmark innovation, the 'AbClick' third-generation 해시 게임 바카라 linker technology, facilitates selective drug conjugation without modifying antibodies. The patented AbClick Pro and Standard platforms enable the regulation of 해시 게임 바카라 in vivo half-life, a crucial advancement in 해시 게임 바카라 technology showcased through collaboration with Lonza, a leading 해시 게임 바카라-focused CDMO.
Notably, AbTis is actively developing 'AT-211 (development code name),' a Claudin 18.2 해시 게임 바카라 candidate targeting gastric and pancreatic cancers, based on the AbClick platform. Anticipated completion of preclinical studies for AT-211 sets the stage for Dong-A ST's objective to initiate clinical phase 1 trial plans (IND) in 2024.
Jae-Hong Park, the Head of R&D (CEO) at Dong-A ST, commented, “In the dynamic landscape of global pharmaceutical competition for 해시 게임 바카라 technology, Dong-A ST's acquisition of AbTis aims to preempt the market, enhancing our competitive edge.” He added, “Our commitment remains steadfast in elevating Dong-A ST to a global pharmaceutical leader through innovative drug development, offering patients the pinnacle of treatment options.”